Antibody Responses to SARS-COV-2 of COVID-19 Patients Based on the Disease Severity
DOI:
https://doi.org/10.24293/ijcpml.v29i1.1951Keywords:
Antibody, SARS-COV-2, severityAbstract
Any individual infected by COVID-19 can suffer various degrees of disease such as asymptomatic symptoms, mild, moderate or severe. Response to the antibody formation in the human body can be affected by the severity of COVID-19. Many researchers have stated that patients suffering a severe COVID-19 had a more significant antibody response, proven by higher antibody titers than those suffering mild or moderate severity. This research aimed to observe the different antibody responses in COVID-19 patients based on the severity of the disease. The research was a retrospective study with a cross-sectional design. The inclusion criteria were confirmed SARS-COV-2 patients determined by RT-PCR test results with age ≥18 years old and a complete medical record taken from electronic medical records and Laboratory Information System (LIS). This study involved 100 COVID-19 patients consisting of 51% non-severe and 49% severe COVID-19. Patients in the non-severe group had a relatively lower IgM and IgG antibody response than patients in the severe group. It could be th primarily observed at the time of antibody measurement > 15 day of symptoms onset (p<0.05).Downloads
References
Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel Coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol, 2020; 92(6): 568-76.
Wang D, Hu B, Hu C, Zhu F, Liu X, et al. Clinical characteristics of 138 hospitalized patients with 2019
novel Coronavirus–infected pneumonia in Wuhan, China. JAMA, 2020; 323(11): 1061.
Kemenkes RI. Pedoman pencegahan dan pengendalian Coronavirus Disease (COVID-19). Revisi ke-5, Kementrian Kesehatan RI, 2020; 16-7.
World Health Organization. Diagnostic testing for SARS-CoV-2: Interim guidance, Sept 11 2020. Geneva, World Health Organization, 2020. (WHO/2019-nCoV/laboratory/2020.6). Available from:
https://apps.who.int/iris/handle/10665/334254 (accessed Nov 24, 2021).
Kolifarhood G, Aghaali M, Mozafar SH, Taherpour N, Rahimi S, et al. Epidemiological and clinical aspects of COVID-19; A narrative review. Arch Acad Emerg Med [Internet]. 2020. Available from: https://journals.sbmu.ac.ir/aaem/index.php/AAEM/article/view/620 (accessed Nov 24, 2021).
Suhandynata R, Hoffman M, Kelner M, McLawhon R, Reed S, Fitzgerald R. Longitudinal monitoring of
SARS-CoV-2 IgM and IgG seropositivity to detect COVID-19. The Journal of Applied Laboratory Medicine, 2020; 5(5): 908-920.
Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, et al. Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLos One, 2020; 15(12): e0244126.
Nuccetelli M, Pieri M, Grelli S, Ciotti M, Miano R, et al. SARS-CoV-2 infection serology: A useful tool to
overcome lockdown?. Cell Death Discovery, 2020; 6: 1.
Kowitdamrong E, Puthanakit T, Jantarabenjakul W, Prompetchara E, Suchartlikitwong P, et al. Antibody responses to SARS-CoV-2 in patients with differing severities of Coronavirus disease 2019. PLos One, 2020; 15(10): e0240502.
Long Q, Liu B, Deng H, Wu G, Deng K, Chen Y, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nature Medicine, 2020; 26(6): 845-848.
Yongchen Z, Shen H, Wang X, Shi X, Li Y, Yan J, et al. Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. Emerg Microbes Infect. 2020; 9(1): 833–6.
Mindray leaflets. SARS-COV-2 IgG & IgM (CLIA). Accessed Nov 24, 2021.
Selanno Y, Widyaningsih Y, Esa T, Arif M. Analysis of neutrophil-lymphocyte ratio and absolute
lymphocyte count as predictors of severity of COVID-19 patients. Indonesian Journal of Clinical Pathology and Medical Laboratory. 2021; 27(2): 184 – 9.
Hu W, Howell J, Ozturk T, Benameur K, Bassit L, et al. Antibody profiles according to mild or severe
SARS-CoV-2 infection, Atlanta, Georgia, USA, 2020. Emerging Infectious Diseases, 2020; 26(12): 2974-2978.
Liu X, Wang J, Xu X, Liao G, Chen Y, Hu CH. Patterns of IgG and IgM antibody response in COVID-19 patients. Emerg Microbes Infect. 2020; 9(1): 1269-1274.
Markewitz R, Torge A, Wandinger K, Pauli D, Franke A, et al. Clinical correlates of anti-SARS-CoV-2 antibody profiles in Spanish COVID-19 patients from a high incidence region. Scientific Reports, 2021; 11: 1.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.